San Diego-dependent Viking Therapeutics marked by itself as a serious competitor from the weight loss drug industry in February after revealing promising details from the mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection and in March the company u